SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 200.30% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Jefferies Financial Group started coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price objective for the company. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Citigroup initiated coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target for the company. Chardan Capital boosted their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock opened at $3.33 on Monday. The stock has a market cap of $254.63 million, a P/E ratio of -1.58 and a beta of 0.54. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics has a 12-month low of $1.60 and a 12-month high of $6.60. The business’s 50 day moving average is $3.70 and its 200-day moving average is $3.85.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Equities research analysts predict that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

A number of hedge funds have recently modified their holdings of SABS. Commodore Capital LP bought a new position in SAB Biotherapeutics in the 3rd quarter valued at about $8,847,000. Simplify Asset Management Inc. bought a new stake in shares of SAB Biotherapeutics during the fourth quarter worth approximately $779,000. Propel Bio Management LLC bought a new stake in shares of SAB Biotherapeutics during the fourth quarter worth approximately $2,442,000. Jefferies Financial Group Inc. acquired a new position in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $2,170,000. Finally, Perceptive Advisors LLC grew its position in shares of SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after purchasing an additional 5,628,533 shares during the last quarter. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.